Simultaneous Occurrence of HER2 Mutations in EGFR Mutant NSCLC: Case Reports

IF 3.5 Q2 ONCOLOGY JTO Clinical and Research Reports Pub Date : 2024-12-01 Epub Date: 2024-09-07 DOI:10.1016/j.jtocrr.2024.100719
Blerina Resuli MD , Diego Kauffmann-Guerrero MD , Jürgen Behr MD , Amanda Tufman MD
{"title":"Simultaneous Occurrence of HER2 Mutations in EGFR Mutant NSCLC: Case Reports","authors":"Blerina Resuli MD ,&nbsp;Diego Kauffmann-Guerrero MD ,&nbsp;Jürgen Behr MD ,&nbsp;Amanda Tufman MD","doi":"10.1016/j.jtocrr.2024.100719","DOIUrl":null,"url":null,"abstract":"<div><div><em>HER2</em> mutation and amplification have been identified as distinct molecular targets in lung cancer with different therapeutic and prognostic values. The coexistence of <em>HER2</em> and <em>EGFR</em> mutations is extremely rare, and therefore, no data exist on the best treatment in these cases.</div></div>","PeriodicalId":17675,"journal":{"name":"JTO Clinical and Research Reports","volume":"5 12","pages":"Article 100719"},"PeriodicalIF":3.5000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"JTO Clinical and Research Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2666364324000894","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/9/7 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

HER2 mutation and amplification have been identified as distinct molecular targets in lung cancer with different therapeutic and prognostic values. The coexistence of HER2 and EGFR mutations is extremely rare, and therefore, no data exist on the best treatment in these cases.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
表皮生长因子受体突变 NSCLC 中同时出现 HER2 突变:病例报告
HER2 基因突变和扩增已被确定为肺癌中不同的分子靶点,具有不同的治疗和预后价值。HER2 和表皮生长因子受体(EGFR)突变同时存在的情况极为罕见,因此目前还没有关于这些病例最佳治疗方法的数据。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
4.20
自引率
0.00%
发文量
145
审稿时长
19 weeks
期刊最新文献
Atezolizumab Combined With Cisplatin Plus Vinorelbine as Adjuvant Therapy for Completely Resected NSCLC With EGFR Mutation (West Japan Oncology Group 11719L: ADJUST Study) Treatment Timeliness in Extensive-Stage SCLC and Impact on Survival: A Registry-Based Observational Study Impacts of Multidisciplinary Lung Cancer Meeting Presentation in a Clinical Quality Registry Cost-Effectiveness of Perioperative Immune Checkpoint Therapy for NSCLC in Japan, the United States, and Brazil Brief Report: Real-World Outcomes in Patients Living With Human Immunodeficiency Virus and Lung Cancer Treated With Immune Checkpoint Inhibitors
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1